益生菌对于高血压2级患者炎症标志物表达水平的影响及血压控制有效率研究

Effects of Probiotics on the Expression Levels of Inflammatory Markers and the Effective Rate of Blood Pressure Control in Patients with Grade 2 Hypertension

摘要: 目的：探讨乳双歧杆菌Probio-M8联合基础降压药物对高血压2级患者炎症标志物表达水平及血压控制有效率的影响。方法：选取2024年1月至2024年12月收治的100例高血压2级患者，采用随机数字表法分为观察组和对照组，每组各50例。对照组给予基础降压药物治疗，观察组在对照组治疗基础上联合乳双歧杆菌Probio-M8干预，两组均持续治疗3个月。比较两组患者治疗前后炎症标志物[系统性免疫炎症指数(SII)、系统性炎症反应指数(SIRI)]水平、血压水平及血压控制效果，将生活方式依从性作为协变量纳入统计分析。结果：治疗后，观察组SII、SIRI水平均显著低于对照组，收缩压、舒张压降低幅度均显著大于对照组，血压控制有效率(84.00%)显著高于对照组(60.00%) (均P < 0.05)；两组患者生活方式依从性评分均较治疗前显著提高(P < 0.05)，但组间治疗前后评分及提升幅度比较差异无统计学意义(P > 0.05)；校正生活方式依从性后，观察组炎症标志物水平及血压控制优势仍存在(P < 0.05)。结论：乳双歧杆菌Probio-M8联合基础降压药物治疗高血压2级患者，可有效降低炎症标志物表达水平，提升血压控制效果，该疗效独立于生活方式依从性，是一种安全有效的联合治疗方案，值得临床推广应用。

Abstract: Objective: This paper aims to study Bifidobacterium animalis Probio-M8 + basic antihypertensive drugs on inflammatory markers and BP control in grade 2 hypertension. Methods: 100 patients with grade 2 hypertension admitted from January 2024 to December 2024 were randomly divided into two groups (50 cases each) by random number table method. The control group was given basic antihypertensive drug treatment, and the observation group was given additional Bifidobacterium animalis Probio-M8 intervention on the basis of the treatment of the control group. Both groups were treated continuously for 3 months. A standardized questionnaire was used to quantitatively evaluate patients' lifestyle compliance. The levels of inflammatory markers [systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI)], blood pressure levels and blood pressure control effects before and after treatment were compared between the two groups, and lifestyle compliance was included in the statistical analysis as a covariate. Results: After treatment, the levels of SII and SIRI in the observation group were significantly lower than those in the control group, the reduction ranges of systolic blood pressure and diastolic blood pressure were significantly greater than those in the control group, and the blood pressure control efficiency (84.00%) was significantly higher than that in the control group (60.00%) (all P < 0.05); the lifestyle compliance scores of both groups were significantly improved after treatment compared with before (P < 0.05), but there was no significant difference in the scores and improvement ranges between the two groups before and after treatment (P > 0.05); after adjusting for lifestyle compliance, the advantages of the observation group in inflammatory marker levels and blood pressure control still existed (P < 0.05). Conclusion: Bifidobacterium animalis Probio-M8 combined with basic antihypertensive drugs in the treatment of patients with grade 2 hypertension can effectively reduce the expression level of inflammatory markers and improve the effect of blood pressure control. This curative effect is independent of lifestyle compliance, and it is a safe and effective combined treatment plan worthy of clinical promotion and application.